# Jazz Pharmaceuticals plc

Summary updated: 2026-10-02T12:26:59.514184Z
Canonical: https://finbar.com/research/companies/jazz-pharmaceuticals-plc

## Overview

Jazz Pharmaceuticals plc is a global biopharmaceutical company that develops and commercializes medicines, with a focus on serious and often rare conditions across neuroscience and oncology, including epilepsies, sleep disorders and cancers. Its stated purpose is “to innovate to transform the lives of patients and their families.” [1](https://app.finbar.com/go?id=P145689490)[2](https://www.jazzpharma.com/about)

The company has direct commercial operations in the U.S., Europe, Australia and Canada, and reaches additional markets through distributors. [3](https://app.finbar.com/go?id=P111202795) For the six months ended June 30, 2026, Jazz reported revenue of $2.277 billion. [4](https://app.finbar.com/go?id=T16672575) It had approximately 2,890 employees worldwide as of December 31, 2025. [5](https://app.finbar.com/go?id=P114575213)
[1](https://app.finbar.com/go?id=P145689490)[2](https://www.jazzpharma.com/about)[3](https://app.finbar.com/go?id=P111202795)[4](https://app.finbar.com/go?id=T16672575)[5](https://app.finbar.com/go?id=P114575213)[2](https://www.jazzpharma.com/about)

## Products & services

Jazz Pharmaceuticals’ sleep products include Xywav, an oral solution of calcium, magnesium, potassium and sodium oxybates, approved for cataplexy or excessive daytime sleepiness in narcolepsy and for idiopathic hypersomnia in adults; it contains 92% less sodium than Xyrem at comparable doses. Xyrem is sodium oxybate oral solution for narcolepsy. Both are distributed through a central pharmacy under FDA-required REMS requirements. [6](https://app.finbar.com/go?id=P145689507)[7](https://app.finbar.com/go?id=P145689506)[8](https://app.finbar.com/go?id=P145689510)[9](https://app.finbar.com/go?id=P113095924) Epidiolex in the United States, marketed as Epidyolex in certain other markets, is cannabidiol oral solution for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex. [10](https://app.finbar.com/go?id=P53669058)[11](https://app.finbar.com/go?id=P40995019)

The oncology and rare-disease portfolio includes Zepzelca (lurbinectedin) for metastatic small-cell lung cancer after platinum-based chemotherapy, and, since October 2025, as first-line maintenance treatment with atezolizumab-based therapy for eligible extensive-stage disease. [12](https://app.finbar.com/go?id=P145689530) Rylaze/Enrylaze is recombinant asparaginase used in multi-agent chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when patients are hypersensitive to or experience silent inactivation of E. coli-derived asparaginase. Defitelio (defibrotide) is used for hepatic veno-occlusive disease/sinusoidal obstruction syndrome, while Vyxeos is a liposomal daunorubicin/cytarabine formulation for infusion. [13](https://app.finbar.com/go?id=P55621795)[14](https://app.finbar.com/go?id=P53303259)[15](https://app.finbar.com/go?id=P145689565) Ziihera (zanidatamab-hrii) is a HER2-directed bispecific antibody approved in the United States for certain previously treated HER2-positive biliary tract cancers; Modeyso (dordaviprone) is a ClpP protease activator approved for eligible patients with H3 K27M-mutant diffuse midline glioma. [16](https://app.finbar.com/go?id=P145689509)[17](https://app.finbar.com/go?id=P145689524)[18](https://app.finbar.com/go?id=T16672572) Jazz also identifies CombiPlex as a drug-delivery technology platform. [19](https://app.finbar.com/go?id=P66956453)

For the six months ended June 30, 2026, reported net product sales were $879.4 million for Xywav, $61.7 million for Xyrem, and $541.9 million for Epidiolex/Epidyolex. [4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575) Oncology and rare-disease product sales included $206.8 million for Zepzelca, $203.2 million for Rylaze/Enrylaze, $109.4 million for Defitelio, $89.6 million for Modeyso, $58.0 million for Vyxeos, and $28.7 million for Ziihera. [4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575) Total net product sales were $2,181.4 million for the period. [4](https://app.finbar.com/go?id=T16672575)
[6](https://app.finbar.com/go?id=P145689507)[7](https://app.finbar.com/go?id=P145689506)[8](https://app.finbar.com/go?id=P145689510)[9](https://app.finbar.com/go?id=P113095924)[10](https://app.finbar.com/go?id=P53669058)[11](https://app.finbar.com/go?id=P40995019)[12](https://app.finbar.com/go?id=P145689530)[13](https://app.finbar.com/go?id=P55621795)[14](https://app.finbar.com/go?id=P53303259)[15](https://app.finbar.com/go?id=P145689565)[16](https://app.finbar.com/go?id=P145689509)[17](https://app.finbar.com/go?id=P145689524)[18](https://app.finbar.com/go?id=T16672572)[19](https://app.finbar.com/go?id=P66956453)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)[4](https://app.finbar.com/go?id=T16672575)

## Geographic presence

Jazz Pharmaceuticals plc is headquartered in Dublin, Ireland, and has U.S. operations in Palo Alto and Carlsbad, California; Philadelphia, Pennsylvania; and Durham, North Carolina. Its reported office locations also include Cambridge and London in the U.K., Vancouver, Canada, and Villa Guardia, Italy. [20](https://app.finbar.com/go?id=P99222215)[21](https://www.sec.gov/Archives/edgar/data/1232524/000162828026027205/jazz-20251231.htm) The company says its medicines are available in nearly 100 countries, with a footprint spanning Europe, North America and Australia and expansion into Japan. [22](https://www.jazzpharma.com/about/global-footprint)

Manufacturing and development locations include Athlone, Ireland, where Jazz manufactures Xywav and Xyrem; Villa Guardia, Italy, where it produces defibrotide drug substance; and Kent Science Park in the U.K., which supports production of Epidiolex/Epidyolex and development of product candidates. [23](https://app.finbar.com/go?id=P3907227) Jazz reports one pharmaceutical-products business segment; the reviewed filings do not provide revenue by country or region, or employee distribution by geography. [24](https://app.finbar.com/go?id=P24266167)
[20](https://app.finbar.com/go?id=P99222215)[21](https://www.sec.gov/Archives/edgar/data/1232524/000162828026027205/jazz-20251231.htm)[22](https://www.jazzpharma.com/about/global-footprint)[23](https://app.finbar.com/go?id=P3907227)[24](https://app.finbar.com/go?id=P24266167)[22](https://www.jazzpharma.com/about/global-footprint)[21](https://www.sec.gov/Archives/edgar/data/1232524/000162828026027205/jazz-20251231.htm)

## Business segments

For FY2025, Jazz Pharmaceuticals plc reported one business segment: the identification, development, and commercialization of pharmaceutical products addressing unmet medical needs. Its neuroscience, oncology, and hematology activities are portfolio or therapeutic-area groupings, not separately reported business segments. [24](https://app.finbar.com/go?id=P24266167)[25](https://app.finbar.com/go?id=T1009914)

The single segment represents the company’s reported business as a whole—effectively 100% of consolidated operations. Jazz does not disclose separate segment contribution percentages by therapeutic area. Its portfolio includes products for sleep disorders and seizure conditions, cancers, and hematologic malignancies. [24](https://app.finbar.com/go?id=P24266167)[25](https://app.finbar.com/go?id=T1009914)
[24](https://app.finbar.com/go?id=P24266167)[25](https://app.finbar.com/go?id=T1009914)

## Company history

Jazz Pharmaceuticals was founded in 2003. In 2005, it acquired Orphan Medical, including Xyrem, and went public on Nasdaq in 2007. [26](https://www.jazzpharma.com/about/history)[27](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-inc-announces-initial-public-offering)

In 2012, Jazz Pharmaceuticals, Inc. merged with Azur Pharma; the combined company adopted the name Jazz Pharmaceuticals plc, with the plc becoming the parent and successor. Jazz expanded further with the 2012 acquisition of EUSA Pharma and, in 2014, Gentium, adding the oncology medicine Defitelio. [28](https://app.finbar.com/go?id=P63724361)[29](https://app.finbar.com/go?id=P25867857)[26](https://www.jazzpharma.com/about/history)

Jazz agreed to acquire Celator Pharmaceuticals in 2016 and completed the transaction that year; its cancer medicine Vyxeos received FDA approval in 2017. In 2021, Jazz completed its acquisition of GW Pharmaceuticals, adding Epidiolex to its portfolio. Renée Gala became president and CEO in August 2025, succeeding co-founder Bruce Cozadd. [30](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-and-celator-pharmaceuticals-announce/)[31](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-plc-announces-results-tender-offer-purchase/)[32](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-fda-approval-vyxeostm)[33](https://www.jazzpharma.com/comp_announcements/transforming-together-what-our-recent-acquisition-means-patients-and-our-people)[34](https://app.finbar.com/go?id=P117918565)
[28](https://app.finbar.com/go?id=P63724361)[29](https://app.finbar.com/go?id=P25867857)[34](https://app.finbar.com/go?id=P117918565)[26](https://www.jazzpharma.com/about/history)[27](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-inc-announces-initial-public-offering)[30](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-and-celator-pharmaceuticals-announce/)[31](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-plc-announces-results-tender-offer-purchase/)[32](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-fda-approval-vyxeostm)[33](https://www.jazzpharma.com/comp_announcements/transforming-together-what-our-recent-acquisition-means-patients-and-our-people)

## Sources

1. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689490)
2. [www.jazzpharma.com](https://www.jazzpharma.com/about)
3. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P111202795)
4. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16672575)
5. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P114575213)
6. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689507)
7. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689506)
8. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689510)
9. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P113095924)
10. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P53669058)
11. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P40995019)
12. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689530)
13. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P55621795)
14. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P53303259)
15. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689565)
16. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689509)
17. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145689524)
18. [Jazz Pharmaceuticals plc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16672572)
19. [Jazz Pharmaceuticals plc — Presentation (2025 Y), p7](https://app.finbar.com/go?id=P66956453)
20. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P99222215)
21. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1232524/000162828026027205/jazz-20251231.htm)
22. [www.jazzpharma.com](https://www.jazzpharma.com/about/global-footprint)
23. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P3907227)
24. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P24266167)
25. [Jazz Pharmaceuticals plc — Full financial report (2025 Y)](https://app.finbar.com/go?id=T1009914)
26. [www.jazzpharma.com](https://www.jazzpharma.com/about/history)
27. [investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-inc-announces-initial-public-offering)
28. [Jazz Pharmaceuticals plc — Full financial report (2016 Y)](https://app.finbar.com/go?id=P63724361)
29. [Jazz Pharmaceuticals plc — Full financial report (2016 Y)](https://app.finbar.com/go?id=P25867857)
30. [investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-and-celator-pharmaceuticals-announce/)
31. [investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-plc-announces-results-tender-offer-purchase/)
32. [investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-fda-approval-vyxeostm)
33. [www.jazzpharma.com](https://www.jazzpharma.com/comp_announcements/transforming-together-what-our-recent-acquisition-means-patients-and-our-people)
34. [Jazz Pharmaceuticals plc — Transcript (2025 Q 2)](https://app.finbar.com/go?id=P117918565)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.